| 臺大學術典藏 |
2022-05-10T08:10:07Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee C.K.; Davies L.; Wu Y.-L.; Mitsudomi T.; Inoue A.; Rosell R.; Zhou C.; Nakagawa K.; Thongprasert S.; Fukuoka M.; Lord S.; Marschner I.; YU-KANG TU; Gralla R.J.; Gebski V.; Mok T.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-04-23T05:56:24Z |
Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis
|
Kok P.-S.;Lee K.;Lord S.;Chih-Hsin Yang;Rosell R.;Goto K.;John T.;Wu Y.-L.;Mok T.S.K.;Lee C.K.; Kok P.-S.; Lee K.; Lord S.; CHIH-HSIN YANG; Rosell R.; Goto K.; John T.; Wu Y.-L.; Mok T.S.K.; Lee C.K. |
| 臺大學術典藏 |
2020-05-26T09:26:41Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Chih-Hsin Yang;Mok T;Gebski V;Gralla R.J;Tu Y.-K;Marschner I;Lord S;Fukuoka M;Thongprasert S;Nakagawa K;Zhou C;Rosell R;Inoue A;Mitsudomi T;Wu Y.-L;Davies L;Lee C.K; Lee C.K; Davies L; Wu Y.-L; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu Y.-K; Gralla R.J; Gebski V; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:39Z |
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non?�Small Cell Lung Cancer?�A Meta-Analysis
|
Chih-Hsin Yang;Mok T;Gebski V;Links M;Lord S;Man J;Lee C.K; Lee C.K; Man J; Lord S; Links M; Gebski V; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic review and meta-analysis
|
Chih-Hsin Yang;Mok T;Gralla R.J;Herbst R.S;Gebski V;Links M;Cooper W;Lord S;Man J;Lee C.K; Lee C.K; Man J; Lord S; Cooper W; Links M; Gebski V; Herbst R.S; Gralla R.J; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:28Z |
The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer
|
Chih-Hsin Chih-Hsin Yang;Mok T;Gralla R;Gebski V;Davies L;Asher R;Mitsudomi T;Fukuoka M;Rosell R;Sequist L;Wu Y.L;Marschner I;Lord S;Lee C.K; Lee C.K; Lord S; Marschner I; Wu Y.L; Sequist L; Rosell R; Fukuoka M; Mitsudomi T; Asher R; Davies L; Gebski V; Gralla R; Mok T; Chih-Hsin CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:19Z |
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer
|
Woodford R;Loh Y;Lee J;Cooper W;Marschner I;Lewis C.R;Millward M;Lord S;Gralla R.J;Chih-Hsin Yang;Mok T;Lee C.K.; Woodford R; Loh Y; Lee J; Cooper W; Marschner I; Lewis C.R; Millward M; Lord S; Gralla R.J; CHIH-HSIN YANG; Mok T; Lee C.K. |
| 臺大學術典藏 |
2018-09-10T18:02:31Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee, C.K. ; Davies, L. ; Wu, Y.-L. ; Mitsudomi, T. ; Inoue, A. ; Rosell, R. ; Zhou, C. ; Nakagawa, K. ; Thongprasert, S. ; Fukuoka, M. ; Lord, S. ; Marschner, I. ; Tu, Y.-K. ; Gralla, R.J. ; Gebski, V. ; Mok, T. ; Yang, J.C.-H.; YU-KANG TU |
